Brief: Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial Of PBFT02 In FTD-GRN
20/12/2023 12:24
Dec 20 (Reuters) - Passage Bio Inc PASG.O :
* PASSAGE BIO ANNOUNCES PROMISING INITIAL DATA FROM PHASE
1/2
CLINICAL TRIAL OF PBFT02 IN FTD-GRN AND UPDATED STRATEGIC
PRIORITIES
* PASSAGE BIO - DOSE 1 OF PBFT02 ACHIEVED SUPRAPHYSIOLOGIC
CSF
PROGRANULIN LEVELS IN EACH OF FIRST THREE TREATED PATIENTS AT 30
DAYS AFTER TREATMENT
* PASSAGE BIO INC - DOSE 1 OF PBFT02 WAS GENERALLY
WELL-TOLERATED
IN PATIENTS WHO RECEIVED AN ENHANCED STEROID REGIMEN FOR
IMMUNOSUPPRESSION
Source text for Eikon: ID:nGNX6hfPBc
Further company coverage: PASG.O
((Reuters.Briefs@thomsonreuters.com;))